Bruker Corporation and Canadian biotechnology firm AbCellera announced a global settlement of their patent litigation on December 18, 2025. The agreement resolves a dispute that had been pending between the two companies for several years and ends the legal conflict over a key microfluidic technology.
The settlement includes a $36 million upfront payment from Bruker to AbCellera and a royalty structure that will apply to all future sales of Bruker’s Beacon Optofluidic platform products. The royalty payments will continue for the life of the licensed patents, providing AbCellera with a recurring revenue stream while granting Bruker a license to use the patented technology.
The patent at the center of the dispute is U.S. Patent No. 10,087,408, which covers microfluidic devices for culturing and recovering cells. Bruker had previously claimed the patent was prior art, but a federal appeals court rejected that claim in May 2025, strengthening AbCellera’s position.
The settlement delivers significant business implications for both parties. For AbCellera, the upfront cash injection improves liquidity in a period of declining revenue growth and negative margins, while the royalty stream offers a new source of income. For Bruker, the license removes a major legal risk and allows the company to focus on expanding its Beacon Optofluidic platform without the distraction of litigation. The agreement also signals a broader trend of resolving high‑profile patent disputes through negotiated settlements rather than prolonged court battles.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.